Skip to content

PolitiKit

Lobbying by Amgen Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Corporation

Amgen Canada Inc.

Meetings this Parliament
41
With MPs
11
Since Nov 2021
70
Active registrations
1

Most recent reported meeting: Sep 10, 2026.

Registrations in effect

In-house (corporation) In effect since Aug 10, 2026

Filed by Ugur Gunaydin, General Manager, Canada

Lobbyists

  • Angela Behboodi · Government Affairs Director Former public office holder

    Formerly Senior Trade Policy Officer, Trade, Global Affairs Canada (2018–2019)

    Formerly Senior Trade Policy Officer, Trade, Global Affairs Canada (2002–2013)

  • John Brenton · Senior Manager, Value Access and Policy
  • John Snowden · Executive Director, Value, Access and Policy
  • Nathan Michaels · Senior Manager, Government Affairs
  • Ugur Gunaydin · General Manager, Canada

Institutions they may lobby: Canada Economic Development for Quebec Regions, Canadian Institutes of Health Research (CIHR), Employment and Social Development Canada (ESDC), Federal Economic Development Agency for Southern Ontario (FedDev), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Invest in Canada Hub, Pacific Economic Development Canada (PacifiCan), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)

What they're lobbying on (14)
  • Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy and opportunities for investment.
  • Communicating with government officials about improved health outcomes, including, but not limited to (i) expanding equitable access to innovative therapies, diagnostics and vaccines, (ii) promoting pricing reform, (iii) enhancing health security, including via the Health Emergency Readiness Canada ("HERC") Agency and (iv) promoting regulatory efficiency and modernization, including through the Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.
  • Communicating with government officials about the implementation and expansion of the national pharmacare program, including as it relates to the Pharmacare Act, S.C. 2024, c. 24.
  • Communicating with government officials about the implementation, renewal and expansion of the "National Strategy for Drugs for Rare Diseases" (2023).
  • Communicating with government officials about international trade agreements, including the Canada-United States-Mexico Agreement (CUSMA), formerly known as the North American Free Trade Agreement (NAFTA), more specifically as it relates to trade in the life sciences and biopharmaceutical sectors.
  • Communicating with government officials about international trade, more specifically tariffs and non-tariff trade barriers affecting the life sciences and biopharmaceutical sectors.
  • Communicating with government officials about regulations, guidelines, reviews, references and reporting requirements issued by and/or related to the Patented Medicine Prices Review Board ("PMPRB").
  • Communicating with government officials about regulations related to patented medicines, including the "Patented Medicines (Notice of Compliance) Regulations" (SOR/93-133) under the Patent Act.
  • Communicating with government officials about a national pharmaceutical strategy, more specifically as it relates to (i) enhanced access to orphan drugs and (i) incentives for the development of rare disorder treatments.
  • Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products.
  • Communicating with government officials about federal healthcare plans and benefits.
  • Communicating with government officials about the Government of Canada's "Biomanufacturing and Life Sciences Strategy" (2021).
  • Communicating with government officials about programs, reports, reviews and policies issued by or related to Canada's Drug Agency (formerly known as the Canadian Agency for Drugs and Technologies in Health).
  • Communicating with government officials about the pan-Canadian Health Data Strategy, more specifically about health data foundations.

Registration 952471-15332-40. Look it up in the official Registry

Reported meetings

Spreadsheet

Filed by Ugur Gunaydin (68), Brian Heath (2).

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Karim Bardeesy · Parliamentary Secretary to the Minister of Industry
    • Chase Knight · Parliamentary Secretary Assistant and Parliamentary Affairs Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Lisa Xie · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy. Read more

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Hosai Zurmati Halim · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    Communicating with government officials about improved health outcomes, including, but not limited to (i) expanding equitable access to innovative therapies, diagnostics and vaccines, (ii) promoting pricing reform, (iii) enhancing health security, including via the Health Emergency Readiness Canada ("HERC") Agency and (iv) promoting regulatory efficiency, including through regulatory modernization. Read more

    Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products.

    Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy.

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Greg Orencsak · Deputy Minister, Health Canada (HC)
    • Sarah Lawley · Assistant Deputy Minister, Health Policy Branch, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Products and Food Branch, Health Canada (HC)
    Communicating with government officials about international trade, more specifically tariffs and non-tariff trade barriers affecting the life sciences and biopharmaceutical sectors. Read more

    Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products.

    Communicating with government officials about improved health outcomes, including, but not limited to (i) expanding equitable access to innovative therapies, diagnostics and vaccines, (ii) promoting pricing reform, (iii) enhancing health security, including via the Health Emergency Readiness Canada ("HERC") Agency and (iv) promoting regulatory efficiency, including through regulatory modernization.

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Ritu Banerjee · Interim Head of Health Emergency Readiness Canada, Innovation, Science and Economic Development Canada (ISED)
    Communicating with government officials about improved health outcomes, including, but not limited to (i) expanding equitable access to innovative therapies, diagnostics and vaccines, (ii) promoting pricing reform, (iii) enhancing health security, including via the Health Emergency Readiness Canada ("HERC") Agency and (iv) promoting regulatory efficiency, including through regulatory modernization. Read more

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Paul Moen · Chief of Staff, Innovation, Science and Economic Development Canada (ISED)
    Communicating with government officials about the implementation, renewal and expansion of the "National Strategy for Drugs for Rare Diseases" (2023). Read more

    Communicating with government officials about the implementation and expansion of the national pharmacare program, including as it relates to the Pharmacare Act, S.C. 2024, c. 24.

    Communicating with government officials about international trade, more specifically tariffs and non-tariff trade barriers affecting the life sciences and biopharmaceutical sectors.

    Communicating with government officials about the pan-Canadian Health Data Strategy, more specifically about health data foundations.

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Tom Kmiec · Member of Parliament for Calgary Shepard
    Communicating with government officials about the implementation, renewal and expansion of the "National Strategy for Drugs for Rare Diseases" (2023).

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    Communicating with government officials about international trade, more specifically tariffs and non-tariff trade barriers affecting the life sciences and biopharmaceutical sectors. Read more

    Communicating with government officials about the implementation and expansion of the national pharmacare program, including as it relates to the Pharmacare Act, S.C. 2024, c. 24.

    Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products.

    Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy.

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Yash Nanda · Policy Advisor, Prime Minister's Office (PMO)
    Communicating with government officials about international trade, more specifically tariffs and non-tariff trade barriers affecting the life sciences and biopharmaceutical sectors. Read more

    Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products.

    Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy.

    Communicating with government officials about the implementation and expansion of the national pharmacare program, including as it relates to the Pharmacare Act, S.C. 2024, c. 24.

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Jade Mallette · Chief of Staff, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products. Read more

    Communicating with government officials about international trade, more specifically tariffs and non-tariff trade barriers affecting the life sciences and biopharmaceutical sectors.

    Communicating with government officials about the implementation and expansion of the national pharmacare program, including as it relates to the Pharmacare Act, S.C. 2024, c. 24.

    Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy.

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products. Read more

    Communicating with government officials about international trade, more specifically tariffs and non-tariff trade barriers affecting the life sciences and biopharmaceutical sectors.

    Communicating with government officials about the implementation and expansion of the national pharmacare program, including as it relates to the Pharmacare Act, S.C. 2024, c. 24.

    Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy.

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products. Read more

    Communicating with government officials about international trade, more specifically tariffs and non-tariff trade barriers affecting the life sciences and biopharmaceutical sectors.

    Communicating with government officials about the implementation and expansion of the national pharmacare program, including as it relates to the Pharmacare Act, S.C. 2024, c. 24.

    Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy.

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Maggie Chi · Member of Parliament for Don Valley North
    Communicating with government officials about international trade, more specifically tariffs and non-tariff trade barriers affecting the life sciences and biopharmaceutical sectors. Read more

    Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products.

    Communicating with government officials about the implementation and expansion of the national pharmacare program, including as it relates to the Pharmacare Act, S.C. 2024, c. 24.

    Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy.

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Special Assistant, Policy, Health Canada (HC)
    Communicating with government officials about the implementation, renewal and expansion of the "National Strategy for Drugs for Rare Diseases" (2023).

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Sarah Viehbeck · Vice-President and Chief Science Officer, Public Health Agency of Canada (PHAC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Policy Branch, Health Canada (HC)
    Communicating with government officials about expanding equitable access to innovative therapies, diagnostics and vaccines. Read more

    Communicating, in general, with government officials about research, development and innovation in Canada's biomedical and biotechnology sector.

    Communicating with government officials about the pan-Canadian Health Data Strategy, more specifically about health data foundations.

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Tom Kmiec · Member of Parliament for Calgary Shepard
    Communicating, in general, with government officials about research, development and innovation in Canada's biomedical and biotechnology sector. Read more

    Communicating with government officials about expanding equitable access to innovative therapies, diagnostics and vaccines.

    Communicating with government officials about a national pharmaceutical strategy, more specifically as it relates to (i) enhanced access to orphan drugs and (i) incentives for the development of rare disorder treatments.

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    Communicating, in general, with government officials about research, development and innovation in Canada's biomedical and biotechnology sector. Read more

    Communicating with government officials about expanding equitable access to innovative therapies, diagnostics and vaccines.

    Communicating with government officials about a national pharmaceutical strategy, more specifically as it relates to (i) enhanced access to orphan drugs and (i) incentives for the development of rare disorder treatments.

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Philip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Life Sciences and Biomanufacturing Readiness, Innovation, Science and Economic Development Canada (ISED)
    Communicating with government officials about international trade agreements, including the Canada-United States-Mexico Agreement (CUSMA), formerly known as the North American Free Trade Agreement (NAFTA), more specifically as it relates to trade in the biopharmaceutical sector. Read more

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Stephen Ellis · Member of Parliament for Cumberland—Colchester, House of Commons
    Communicating, in general, with government officials about research, development and innovation in Canada's biomedical and biotechnology sector.

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Rick Perkins · Member of Parliament for South Shore—St. Margarets, House of Commons
    Communicating, in general, with government officials about research, development and innovation in Canada's biomedical and biotechnology sector.

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Rick Perkins · Member of Parliament for South Shore—St. Margarets, House of Commons
    Communicating, in general, with government officials about research, development and innovation in Canada's biomedical and biotechnology sector.

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Sharon Burey · Senator for Ontario, Senate of Canada

    Health

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Tom Kmiec · Member of Parliament for Calgary Shepard

    Health

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Mohamed-Iqbal Ravalia · Senator for Newfoundland and Labrador, Senate of Canada

    Health

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Paul Moen · Chief of Staff, Employment and Social Development Canada (ESDC)

    Health

    Official report

  • Reported by Ugur Gunaydin · In-house (corporation)

    • Ophelia John · Senior Policy Advisor, Health Canada (HC)

    Health

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.